FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* RASTETTER WILLIAM H					2. Issuer Name and Ticker or Trading Symbol Dare Bioscience, Inc. [DARE]						(Ch	elationship ceck all applic	,	rson(s) to Issu		
(Last) (First) (Middle) C/O DARE BIOSCIENCE, INC.					3. Date of Earliest Transaction (Month/Day/Year) 07/19/2017							Officer below)	(give title	Other (s below)	pecify	
11119 NORTH TORREY PINES ROAD, SUITE 200				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable				
(Street)	LA C	A	92037	07	7/21/2	2017						Line	X Form fi	led by One Repled by More tha	J	
(City)	(S	tate)	(Zip)													
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date				Transactio ate Ionth/Day/\	Execution Date,		Code (Instr. 5)				Beneficia Owned F	es Form ally (D) of Following (I) (II	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code V	, A	Amount	(A) or (D)	Price	Transact	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Yo	ate, Transac Code (In				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amount or Number of Shares		(Instr. 4)		
Option to Purchase Common Stock	\$6.56 ⁽¹⁾	07/19/2017		A		2,000 ⁽²⁾		(3)(4)	07/:	19/2027	Common Stock	2,000	\$0.00	2,000	D	

Explanation of Responses:

- 1. The exercise price reported reflects the 10 for 1 reverse stock split effected by the Corporation on July 20, 2017.
- 2. Dr. Rastetter was awarded options to purchase shares of the Corporation's common stock in connection with his service as a member of the Board of Directors (the "Director Options") pursuant to the Corporation's 2014 Stock Incentive Plan.
- 3. This form amends a Form 4 previously filed for Dr. Rastetter on July 21, 2017, to correct the description of the vesting schedule of the stock options.
- 4. The Director Options will vest in full on the earlier of the one year anniversary of the date of grant or immediately prior to the Corporation's 2018 annual meeting of stockholders.

Remarks:

/s/ Sebastian E. Lucier, Attorney-in-fact 12/08/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.